CastCaller

Psoriasis Pharmaceutical Commercial Casting Call

Casting Calls in Remote | Seeking Actor | Compensation: $ /Day | Apply by Sep 11, 2023
Traditional Broadcast - Non-Union OCP - Session rate: $500/day + 20% - OCP - Usage as described above: $3000 + 20% for two years from date of first use - Usage includes utilization of final art and derivatives of final assets including revisions and cutdowns - Includes materials/communications sent directly to patientsThis is a commercial, non-union project for a pharmaceutical company that is holding one conflict. Talent rates are $500/day + 20% for session rate and $3000 + 20% for two years from date of first use for usage as described. Usage includes Connected TV and OLV, excludes Traditional Broadcast, and includes utilization of final art and derivatives of final assets including revisions and cutdowns, as well as materials/communications sent directly to patients.

Project Name: Psoriasis Pharmaceutical
Project Type: Commercial
Union Status: Non-Union
Conflicts: Pharmaceutical
Exclusivity: Holding one conflict
Psoriasis medicines for all media Usage/Run
Talent Rates:
Non-Union OCP – Session rate: $500/day + 20%
OCP – Usage as described above: $3000 + 20% for two years from date of first use
Renewal Rates: Pending
Use: Stills and Connected TV, Video all Media except Traditional Broadcast 2 years from first date of use
Scope of Use:
All captures for 2 years N.

America unlimited in all media without limitation from date of first use including but not limited to trade and consumer ads, trade and consumer collateral including booklets, brochures, and detail aids, convention panels, posters, premiums, and unlimited electronic media/web including emails, digital collateral, social media, apps and Internet.

Usage includes utilization of final art and derivatives of final assets including revisions and cutdowns.

Includes materials/communications sent directly to patients.

Usage period begins at first use.

– Includes Connected TV and OLV
– Excludes

Share with friends
Published September 4, 2023
Category: Latest

Leave a Reply

Your email address will not be published. Required fields are marked *